Shattuck Labs (NASDAQ:STTK) Given New $8.00 Price Target at Wedbush

Shattuck Labs (NASDAQ:STTK) had its target price hoisted by Wedbush from $4.00 to $8.00 in a report published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other analysts also recently weighed in on the stock. Citigroup lifted their price target on shares of Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. HC Wainwright upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Monday, December 1st. Piper Sandler started coverage on Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Shattuck Labs Price Performance

Shares of STTK opened at $5.99 on Friday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $6.00. The company has a 50-day moving average of $4.17 and a 200 day moving average of $2.83. The firm has a market capitalization of $379.05 million, a price-to-earnings ratio of -7.78 and a beta of 1.55.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of ($1.00) million during the quarter, compared to analysts’ expectations of $0.17 million. On average, equities analysts anticipate that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Turtle Creek Wealth Advisors LLC bought a new position in Shattuck Labs in the third quarter worth about $29,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs in the 3rd quarter valued at about $38,000. Squarepoint Ops LLC bought a new stake in shares of Shattuck Labs in the 3rd quarter valued at about $46,000. Mallini Complete Financial Planning LLC purchased a new position in shares of Shattuck Labs in the 4th quarter worth approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Shattuck Labs in the 4th quarter worth approximately $85,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs News Roundup

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Needham initiated coverage with a “Buy” and a $25.00 price target, a materially higher target that signals strong upside and likely attracted buying interest. Needham Initiation
• Positive Sentiment: Wedbush raised its price target from $4.00 to $8.00 and kept an “Outperform” rating, providing additional analyst support and a nearer-term beat-the-street catalyst. Wedbush Target Raise
• Negative Sentiment: HC Wainwright cut its FY2026–FY2028 EPS forecasts (FY2026 to ($0.83) from ($0.71); FY2027 to ($0.88) from ($0.76); FY2028 to ($1.04) from ($0.90)) while still maintaining a “Buy” rating and a $6 price target — the revisions signal slower expected progress in profitability and could pressure longer-term expectations. HC Wainwright Note
• Negative Sentiment: Shattuck’s published Q4/FY2025 results showed EPS roughly in line with estimates but revenue missed expectations (company reported negative/weak revenue for the quarter vs. consensus), a mixed report that limits upside from fundamentals until revenue trends improve. Q4 & FY2025 Results

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.